A novel variant in MFN2 linked to a lethal disorder of neonatal onset

Authors: Mashiat Zaman[1], Cole Chute[1], Julien L Marcadier[2], S Grewal[1], R Luke Wiseman[3],

Amanda V Tyndall[4], Brenda McInnes[2], A Micheil Innes[5], Francois P Bernier[5], Timothy E. Shutt[6*]

[1]Department of Biochemistry & Molecular Biology, Cumming School of Medicine, Hotchkiss

Brain Institute, Alberta Children's Hospital Research Institute, University of Calgary

[2]Department of Medical Genetics, Cumming School of Medicine, University of Calgary

[3]Department of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, CA

[4]Department of Medical Genetics, Cumming School of Medicine, Alberta Children's Hospital

Research Institute, Hotchkiss Brain Institute, University of Calgary

[5]Departments of Medical Genetics and Pediatrics, Cumming School of Medicine, Alberta

Children's Hospital Research Institute, University of Calgary

[6]Departments of Medical Genetics and Biochemistry & Molecular Biology, Cumming School of

Medicine, Hotchkiss Brain Institute, Snyder Institute for Chronic Diseases, Alberta Children's

Hospital Research Institute, University of Calgary

*Corresponding author (timothy.shutt@ucalgary.ca)

Abstract:

Pathogenic variants in the mitochondrial fusion protein Mitofusin2 typically cause

axonal Charcot-Marie-Tooth disease type 2A (CMT2A), a progressively degenerative peripheral

neuropathy. Here, we present three siblings with a lethal disorder of neonatal onset who

carried a novel homozygous MFN2 variant R334K, which was predicted to be likely pathogenic.

Given the severe clinical presentation, which is atypical of MFN2 variants, further functional

investigations were warranted to confirm the pathogenicity of the R334K variant.

Characterization of patient fibroblasts revealed severe disruptions in all MFN2-related functions

assayed, including mitochondrial fragmentation, altered mito-ER contacts, decreased mtDNA

copy number and size, increased lipid droplet abundance, and reduced mitochondrial

respiration. We also observed reduced Complex I activity, which is noted in cells lacking MFN2,

but is not typical of pathogenic MFN2 variants that cause CMT2A. Notably, re-expression of

MFN2 R334K in MFN2 knockout cells was unable to rescue mitochondrial fragmentation and

the Complex I deficiencies, confirming that the R334K variant is causative of these cellular

phenotypes. Furthermore, disease modelling in *Drosophila melanogaster* demonstrated

functional deficiencies of the R334K variant *in vivo*. Together, these findings confirm that the

MFN2 R334K is a novel pathogenic variant causing severe fatal neonatal disease. Finally, we

show that pharmacological activation of the integrated stress response rescues the defects

caused by MFN2 R334K, offering a potential therapeutic avenue for MFN2 pathology.

Introduction:

Pathogenic variants in *MFN2* cause the hereditary motor sensory neuropathy Charcot-Marie-Tooth disease 2a (CMT2a), which is characterized by progressive neuropathy with distal numbness and weakness. CMT2a is generally considered as an early-onset disease, with symptoms typically appearing around age 10. While CMT2a is most often autosomal dominant (CMT2A2A), there are cases of homozygous or compound heterozygous recessive inheritance (CMT2A2B) [25, 46]. *MFN2* encodes the integral outer mitochondrial membrane (OMM) protein Mitofusin2 (MFN2), initially characterized for its role in mitochondrial fusion [12]. The protein consists of distinct domains, with an N-terminal GTPase domain, followed by two coiled-coil heptad repeat (HR) domains separated by a transmembrane domain.

The clinical presentation of CMT2a can vary widely, where some MFN2 variants are associated with additional clinical features [29, 53, 54]. While there is evidence of specific MFN2 variants leading to severe and early pathology, neonatal lethality is exceedingly rare [7, 13, 15, 21]. Though the reasons for this heterogeneity are unknown, it is notable that MFN2 has several other functions, including mediating mito-ER contacts (MERCs) [10], facilitating mito-lipid droplet contacts [9], participating in mitochondrial transport [40] and being a key regulator of mitophagy [38]. These MFN2 functions also influence downstream processes such as mtDNA regulation [55], cellular Ca^{2+} signalling [1] and mitochondrial bioenergetics [64]. The impact of different MFN2 variants on the various functions of MFN2 is largely unknown [64]. Surprisingly, for the few variants studied, fusion is not always impacted [2, 16, 30, 33, 63], suggesting that other MFN2 functions are likely contributing to MFN2 pathogenesis.

There is currently no specific therapy for MFN2 pathologies. Although several promising preclinical approaches are in development for CMT2A [49, 50, 62], they focus primarily on promoting mitochondrial fusion, rather than other MFN2 functions. Building on the fact that activation of the Integrated Stress Response (ISR) has recently garnered attention for ameliorating mitochondrial dysfunction [1, 31, 40, 54], we recently showed that ISR activation can restore mitochondrial morphology in patient fibroblasts harbouring the pathogenic D414V MFN2 variant [5], as well as MERCs, mitochondrial motility, and mitochondrial respiration in

MFN2 KO cells [8] . ISR activation is mediated by phosphorylation of eIF2α via four kinases that

sense different types of cellular stress (*i.e.*, HRI, GCN2, PERK and PRK), ultimately turning on the

ATF4 transcription factor that engages multiple cellular stress responses. Thus, ISR activation is

a promising therapeutic approach to target mitochondrial dysfunction beyond just impaired

mitochondrial fusion.

In this work, we describe three siblings who presented with severe neonatal

encephalopathy with areflexia, limited spontaneous movements, respiratory failure, severe

hypotonia, arthrogryposis and neonatal demise. All three patients had novel homozygous

variants in MFN2, c.1001G>A, p.(Arg334Lys). We report detailed patient phenotypes and

provide a comprehensive characterization of multiple mitochondrial functions associated with

MFN2 in patient fibroblasts. Using cell and animal modelling, we provide evidence that the

R334K MFN2 variant significantly impacts mitochondrial function, not only explaining the

cellular phenotypes, but also being responsible for the neonatal lethal axonal disease reported

in these three siblings, thus expanding the clinical spectrum of CMT2A. Finally, we show that ISR

activation rescues mitochondrial fragmentation and reduced respiration in R334K patient

fibroblasts, offering a promising therapeutic avenue for MFN2-mediated pathology.

Methods

Genomic analysis

The proband was enrolled into a research study titled Rapid Access for Pediatric Diagnoses Kidomics (RAPiD) at the Alberta Children's Hospital. Formal written consent was provided by the family (mother, father, and proband) for both the RAPiD research exome (study approved by the University of Calgary Conjoint Health Research Ethics Board) sequencing and the clinical whole exome sequencing. DNA was extracted from whole blood samples, and trio exome library preparation was conducted using the xGen Exome Research Panel v1.0 capture kit (Integrated DNA Technologies, Inc., Coralville, IA, USA). Paired-end sequencing was performed on a NextSeq 550 (Illumina, San Diego, CA, USA) in which data was automatically uploaded into BaseSpace Sequencing Hub where alignment, variant calling, and variant interpretation was completed.

Sequence alignment

Amino acid sequence alignments for MFN2 and FOXRED1 were performed on T-COFFEE multiple sequence alignment tool [17]. Protein sequences were collected from the UniProt database [58]. The UniProt Sequence ID's were as follows: Human MFN2: O95140-1; Human MFN1: Q8IWA4; Mouse MFN2: Q80U63; Fish MFN2: A8WIN6; Fly MFN2: Q7YU24; Worm MFN2: Q23424; FXRD1: Q96CU9; FXRD1 [2]: Q96CU9-2 ; FXRD1 [3]: Q96CU9-3; Mouse FXRD1: Q3TQB2; Fish FXRD1: A0A0R4IHD6; Fly FXRD1: Q9VJ10; Worm FXRD1: A0A0V1BI76 .

Cell culture

Skin fibroblasts were cultured in Minimum Essential Media (Gibco™, 11095098), supplemented with 10% Fetal Bovine Serum (FBS) and 10mM Sodium Pyruvate. The cells were maintained at 37°C and 5% CO_2. U2OS cells were maintained in DMEM high-glucose media (Gibco™; 11965118), also at 37°C and 5% CO_2. The following ISR inhibitors/activators were used for the morphology and OCR studies: ISRIB (ISR inhibitor) (Cat# SML0843, Sigma), halofuginone (Cat#50-576-3001, Sigma), #3610 or Parogrelil (139145-27-0, Axon Medchem). For drug

107 treatments the compounds were added at the following doses: ISRIB (200nM), compound

108 #3610 (10uM), Parogrelil (10uM) and Halofuginone (100nM),

Respiration studies

110  Cellular oxygen consumption rates were measured using the Seahorse XFe24

111 Extracellular Flux Analyzer (Agilent Technologies) as previously described [52]. In summary, cells

112 were seeded in the manufacturer provided microplate at 70,000 cells/well and incubated for 24

113 hours at 37°C and 5% CO_2. Subsequently, the growth media was replaced, and cells equilibrated

114 in assay media supplemented with d-Glucose (25 mM), sodium pyruvate (2 mM) and l-

115 Glutamine (4 mM). Oxygen consumption rates were calculated following administration of the

116 following compounds: Oligomycin (1 µg/mL) (Enzo Life Sciences, BML-CM111), Carbonyl

117 Cyanide 4-(trifluoromethoxy) Phenylhydrazone (FCCP, 1 µM) (Enzo life Sciences, BML-CM120)

118 and Antimycin A (1 µM) (Sigma Aldrich, A8674). The data from the Seahorse analyzer was

119 normalized to protein content data for each well measured by BCA assay (Thermo Fisher

120 Scientific, 23225). The Lucid Resipher assay was used for the ISR studies, as previously

121 described [8]. Briefly, 15,000 cells were seeded on a round bottom 96-well cell culture plate

122 (MaxBioChem, MBC.TC.F. 96)and allowed to settle for 18 hours. The ISR inhibitors/activators

123 were added at the following doses: ISRIB (200nM), compound #3610 (10uM), Parogrelil (10uM)

124 and Halofuginone (100nM):, and OCR was measured at 6 hours after treatment. Samples were

125 normalized for total protein content, lysed from the 96-well plate using RIPA buffer (Thermo

126 Scientific™, 89900) using a BCA assay, standardized with BSA (Fisher Scientific, PI23209).

Immunofluorescence and Microscopy

128  20,000 control/patient fibroblasts or U2OS cell lines were seeded on 12mm

129 (Fisherbrand, 12-545-81) coverslips inserted into wells of a 24-well plate (Sarstedt, 83.3922)

130 and incubated for 24 hours at 37°C and 5% CO_2. Cells were fixed with 4% paraformaldehyde

131 (ElectronMicroscopySciences, 15710) at 37°C for 20 minutes, permeabilized using 0.1% Triton®

132 X-100 (MP Biomedicals, 9002-93-1) and blocked with 10% FBS. The mitochondrial network was

133 stained with anti-TOMM20 (Sigma-Aldrich, HPA011562/Santa Cruz Biotechnology, F-10 sc-

134 17764) primary antibodies and visualized using goat anti-rabbit secondary conjugated with

Alexa Fluor 488 (ThermoFisher, A-11034) or goat anti-mouse conjugated Alexa Fluor

(ThermoFisher, A-31571). Mitochondrial nucleoids were visualized using anti-dsDNA antibody

(Developmental Studies Hybridoma Bank, AB_10805293) and goat anti-mouse secondary

conjugated with Alexa fluor 568 (ThermoFisher, A-11004), following permeabilization with 0.2%

Triton® X-100). Lipid droplets were studied using BODIPY™ 493/503 (Invitrogen, D3922). Live

cells were seeded onto 35mm live cell imaging dishes (Cellvis ,D35-20-1.5-N) and allowed to

settle for 24 hours. The BODIPY dye was subsequently added at 10uM concentration and

incubated for 30 minutes, after which the cells were washed three times with culture media

and then imaged. Confocal imaging was performed using Olympus spinning disc confocal.

Confocal imaging was performed using Olympus spinning disc confocal system (Olympus SD

OSR) (UAPON 100XOTIRF/1.49 oil objective). STED imaging was performed using Leica TauSTED

microscope. For the ISR studies, control and patient fibroblasts were seeded at 70,000 cells

onto 35mm live cell imaging dishes (D35-20-1.5-N, Cellvis) and allowed to settle for 24 hours.

Mitochondrial networks were stained with 100nM MitoTracker Green FM (M7514, Life

Technologies) for 30 minutes and subsequently washed with cell culture media three times. . Z-

stacks were captured using confocal imaging was performed using Olympus spinning disc

confocal system (Olympus SD OSR) (UPlanApo. 60X 1.50NA), including a cellVivo live cell

incubator system used to maintain cells at 37°C and 5% CO_2 , Mitochondrial morphology was

qualitatively scored based on appearance categorized into fused/intermediate/fragmented for

150 cells, spread across 3 biological replicates. Quantitative mitochondrial network analyses

were performed using MiNA on FIJI [59], also scored for 150 cells, spread across 3 biological

replicates. Lipid droplets number and size were quantified using the 'analyze particles' tool on

FIJI.

Proximity Ligation Assay:

The proximity ligation assay was performed as mentioned in [54]. All immunostaining

steps, including fixation, blocking and permeabilizing were the same as mentioned for

mitochondrial network studies. The Duolink® In Situ Proximity Ligation Assay (Millipore Sigma)

was used for this. The aforementioned anti-TOMM20 antibody was used to label the

mitochondria, while the ER was labelled using anti-Calnexin (mouse monoclonal, EMD

Millipore: MAB3126 (RRID:AB_2069152). Images were analyzed using confocal microscopy (as

described above) and PLA puncta were analyzed using the 'analyze particles' tool on FIJI.

Western Blot Analysis

Cells grown to the same confluency were collected and RIPA buffer (Thermo Scientific™,

89900) complimented with protease inhibitors (VWR, 97063-010) was used to lyse and collect

the protein extracts. For fly protein, 20 flies were homogenized and sonicated in RIPA buffer

(Thermo Scientific™, 89900). Following quantification of protein concentrations using a BCA

assay, standardized to BSA (Fisher Scientific, PI23209), 50 µg of total protein was loaded on an

SDS-PAGE gel. Subsequently, PVDF membranes (Bio-Rad, 1620177) were used for overnight

transfer of the blots. The blots were probed with the following antibodies: anti-MFN2 (Abnova,

H00009927-M03; 1:1000), anti-MFN1 (Cell Signaling Technology, D6E2S; 1:1000), anti-OPA1 (BD

Transduction Laboratories, 612607; 1:1000), anti-Actin (Sigma, A5316; 1:1000) anti-Actin for fly

membrane (DSHB, JLA20; 1:1000) and cocktail anti-OXPHOS Complex antibody (AbCam,

ab110411; 1:500). Complimentary horseradish peroxidase conjugated antibodies were used:

goat anti rabbit IgG, HRP linked Antibody (Cell Signaling Technology, 7074S) or goat anti-mouse

IgG-HRP (Santa Cruz Biotechnology, sc-2055). Blots were treated with the SuperSignal™ West

Femto Maximum Sensitivity Substrate (Thermo Scientific™, 34095), and luminescence

visualized with an Amersham Imager AI600.

mtDNA Copy Number and mtDNA Deletions Analysis

Total DNA was extracted and purified from control and patient fibroblasts seeded at

30,000 cells using the PureLink Genomic DNA Mini Kit (Thermo Fisher Scientific, K182001) using

the given protocol. Relative mtDNA copy number was analysed using QuantStudio 6 Flex Real-

Time PCR system (Thermo Fisher Scientific). The mtDNA and nuclear encoded housekeeping

gene 18S were amplified using the primers and reaction conditions described in [18]. Long

range PCR reactions were performed to examine mtDNA deletions. The following primers were

used for amplification of the mtDNA: 1482–1516 F:

ACCGCCCGTCACCCTCCTCAAGTATACTTCAAAGG; 1180–1146 R:

ACCGCCAGGTCCTTTGAGTTTTAAGCTGTGGCTCG. The Takara LA Taq Polymerase (Takara Bio,

RR002M) was used with 250ng total cellular DNA. PCR cycling conditions were 94°C for 1 min;

98°C for 10 s and 68°C for 11 min (step 2 and 3- 35 cycles); and a final extension cycle at 72°C

for 10 min, using an Eppendorf® 5331 MasterCycler Gradient Thermal Cycler. PCR products

were visualized by electrophoresis on a 0·6% agarose gel, run for approximately 18 h at 20 V.

Complex-I Activity Assay

The mitochondrial complex-I activity assay was performed using the Complex I Enzyme

Activity Dipstick Assay Kit (AbCam, ab109720) according to manufacturer instructions. Briefly,

50,000 cells were seeded into a six-well plate (Sarstedt, 83.3920) and collected the following

day. 10x Extraction buffer from the kit was added to the cell pellet and subsequently spun at

18,000 x g. Supernatants were collected and following homogenization, control and patient

samples were plated in the plate provided. Subsequently, the dipstick from the plate was added

and incubated for 45 minutes. Following washing procedures, the dipsticks were imaged with

Amersham Imager AI600.

Re-expression of MFN2 R334K in U2OS cells:

U2OS MFN2 knockout cells were a generous gift from Dr. Edward Fon (McGill University,

Canada) [38]. The MFN2 R334K variant was inserted into MFN2 KO cells as previously described

[63]. Briefly, a retroviral plasmid vector (Vector Builder, VB230626-1399nzw) with the MFN2

R334K open reading frame or WT MFN2, followed by an mNeonGreen (after IRES) was virally

inserted into MFN2 KO cells, and cells were sorted for mNeonGreen expression through

fluorescence activated cell sorting. Endogenous expression levels were quantified by western

blot analysis, as described in the western blot section of methods.

***Drosophila* stocks, transgenic lines and experiments**

All *Drosophila* were maintained at 25°C and kept in standard food. Flies were allowed to

lay eggs on standard grape plates with yeast plated for two days before collection. *Drosophila*

stocks for ey3.5-Gal4 (BDSC#8221) was provided by Dr. William Brook (University of Calgary,

Canada), elav-Gal4, tub-Gal4 (BDSC#5138), act5c-Gal4 (BDSC#4414), daGal4, UAS-*mCherry*RNAi

and UAS-*marf* RNAi (31157) [44] was provided by Dr. Savraj Grewal (University of Calgary,

Canada) and tincΔ4Gal4 was provided by Dr. Rolf Bodmer (Sanford Burnham Prebys Medical

Discovery Institute, USA). A second UAS-*marf*RNAi (67158) was purchased from Bloomington

Stock Centre (Indiana University, USA). Flies re-expressing the human MFN2 WT and MFN2

R334K were generated through microinjection (GENOMEPROLAB, Canada). The pGW.UAS

hMFN2 plasmid used for microinjection was provided by Dr. Paul Marcogliese (University of

Manitoba, Canada), which was subsequently mutated by in-fusion cloning (Takara, 638945).

Flies were microinjected on chromosome II using the attp40 landing site, through the phiC31

integration approach. For the survival assay, flies were allowed to lay eggs on grape plates with

yeast paste for 48 hours and subsequently 50 eggs were collected and placed into standard

food. The number of eggs that became pupa were counted and normalized to total number of

eggs collected, for percentage survival. For negative geotaxis studies, 30 newly emerged adult

flies of the respective crosses were placed into a 1000cc cylinder. On a given day, the flies were

gently displaced to the bottom every 3 hours and the percentage of flies that made it past the

10 cm mark after 10 seconds was counted.

Statistical Analyses

All statistical analyses were performed using GraphPad Prism 9.

Results:

Case description:

Proband (P1)

The male proband was born by C-section for preterm labor, breech presentation and
fetal heart rate abnormalities at 35 weeks to a 21-25-year-old G3, P0 mother. The pregnancy
was remarkable only for a mild COVID infection in the first trimester, with three antenatal
ultrasounds reported as completely normal. Decreased fetal movements were noted in the last
4 to 8 weeks of the pregnancy. His birthweight was 2.08 kg (10th percentile), length 46.6 cm
(50th percentile) and his head circumference was 32.1 cm (50th percentile). APGARs were
1,3,3,6 at 1, 5,10 and 15 minutes respectively. He remained flat with no respiratory effort and
was intubated at 6 minutes of life. He remained ventilator dependent and eventually died in
the pediatric intensive care unit at 2-6 weeks of age. On examination, he was noted to have
hypotonia both peripherally and axially with decreased spontaneous movements. He had
bilateral elbow and knee flexion contracures, with limited hip abduction, and talipes
equinovalgus. He was noted to have a bulbous nasal tip, but a complete dysmorphology exam
was not feasible.

Investigations included normal newborn metabolic screening, normal rapid aneuploidy
detection, SNP chromosomal microarray, Prader Willi, DM-1 and SMA. While chromosomal
microarray analysis did not reveal any copy number variation to explain the proband's
phenotype, the SNP component of the analysis revealed three contiguous regions (greater than
10Mb) of absence of heterozygosity (AOH) within chromosomes 1, 3, and 4. Metabolic
investigations revealed normal urine and plasma amino acids and a normal plasma acylcarnitine
profile. Urine organic acids were non diagnostic and plasma 3-methylglutaconic acid and 3-
methylglutaric acid were also normal. EEG was indicative of moderate diffuse/multifocal
cerebral dysfunction with multifocal epileptiform discharges. Brain MRI shortly after birth
showed multiple foci of diffusion restriction due to cytotoxic edema involving the deep and
periventricular white matter in frontoparietal lobes with corresponding intrinsic T1
hyperintensity. There were no overt signs on imaging or MRS to suggest a metabolic cause. A

follow-up brain MRI just prior to death reported interval resolution of the multiple foci of

restricted diffusion in the bilateral centrum semiovale ovale/corona radiata, with a few small

scattered residual centrum semiovale T1 hyperintense foci without restricted diffusion. As

compared to the previous MRI, there was interval development of atrophy of the superior

vermis, seen as increased interfoliate distance. Mild atrophy was also seen involving the lateral

cerebellar hemispheres. The brain stem structures, especially the midbrain and pons, had

reduced volume for patient's age, with prominence of the prepontine cisterns, resulting in

prominence of the posterior fossa CSF spaces without mass effect. The remainder of the

midline structures appeared normal with no Chiari I deformity and a normal pituitary gland. The

corpus callosum was well developed and the remaining brain parenchyma was normal with an

age-appropriate myelination pattern. No new areas of restricted diffusion or abnormal signal

involving the cerebrum or cerebellum were observed and there was no abnormal susceptibility-

related signal loss to suggest blood degradation products. The brain stem structures, especially

the midbrain and pons had reduced volume for the patient's age. Additional imaging of the

patient's spine showed marked smooth hypoplasia and reduced caliber of the thoracic spinal

cord. In addition, the brainstem and thoracic spinal cord reported to be small.

A muscle biopsy was performed shortly before death revealing no definite abnormalities

but coarse NADH, SDH, and COX histochemistries were observed in addition to mild

mitochondrial aggregation in the subarcolemmal spaces with some smaller mitochondria but

normal cristae. There were grouped atrophic fibres and occasional hypertrophic fibres.

He was born to healthy Middle Eastern parents who were known to be distantly

consanguineous. There was no family history of similarly affected children.

Proband's sibling (P2)

The proband's male sibling presented with the same core phenotype of encephalopathy,

hypotonia, hyporeflexia, arthrogryposis. The sibling had an unremarkable prenatal history with

normal anatomy scan. A second scan at revealed breech presentation but otherwise normal

with normal fetal movements. A further scan was appropriate for gestational age and showed

breech presentation. He was born via C-section due to preterm labor with APGARS 1, 2, and 3

at 1, 5 and 10 minutes respectively, with no spontaneous respirations. He was intubated and

admitted to NICU. He required continuous mandatory ventilation. Life sustaining measures

were withdrawn between day 11-15 and the patient died the same day. An autopsy was

declined.

On examination at birth, the baby was noted to be hypotonic with contractures and

decreased range of motion of elbows, hips and knees with bilateral talipes equinovarus. His

birth weight was 2.365kg (<50th percentile), length 48 cm (<90th percentile) and head

circumference 31.4 cm (50th percentile). He had depressed/absent reflexes. Investigations

included a normal newborn metabolic screen, normal lactates, ammonia, and liver enzymes

with a mildly elevated CK. An EEG was consistent with encephalopathy. Brain MRI showed

cerebellar hypoplasia with query germiolytic cysts. An MRI of the spine was normal.

Proband's sibling (P3)

A third affected child presented with very similar features to other affected siblings. Prenatal

ultrasounds at 23-27 weeks revealed suspected club feet, and the fetus was in breech

presentation at 32-36 weeks, which raised concerns regarding a likely recurrence of what was

now clearly suspected to be a recessive disorder. Delivery was by emergent C-section with

APGARS of 1,2,4. The neonatal presentation was very similar to the siblings, with severe

encephalopathy, limited respiratory effort, no large joint spontaneous movements or

spontaneous eye opening, and arthrogryposis requiring admission to NICU for ventilation. No

seizures were identified, and the EEG was encephalopathic with prolonged interburst intervals.

MRI features were also consistent with those of the previous affected children with hypoplasia

of the parietal lobes, cerebellum, and upper cord. The goal of care was changed at 3-7 days of

life, and this girl passed shortly after extubation.

Genetic workup:

Upon initial research RAPID exome sequencing, trio analysis of P1 and parents, who

were distantly consanguineous, detected the homozygous c.1001G>A, p.(Arg334Lys) variant of

uncertain significance in the MFN2 gene. Pathogenic variants in MFN2 are associated with

autosomal dominant and autosomal recessive Charcot-Marie-Tooth disease, axonal, type 2A.

While patients with variants in MFN2 have a heterogeneous clinical presentation with an age of

onset ranging from 1-45 years, previously reported individuals with homozygous or compound

heterozygous variants presented before the age of 10 years [41, 57]. These affected individuals

presented with muscle weakness, distal sensory loss, and normal or mildly decreased nerve

conduction velocity, while the heterozygous parents were reported to be asymptomatic or had

signs of a mild peripheral neuropathy [41]. This variant has not been reported in gnomAD,

ClinVar, or the literature. This missense variant resides near the middle of exon 10 of 19 and

appears to abolish a potential cryptic donor splice site within this exon. The consequence of the

loss of this cryptic donor splice site is unknown. A subsequent clinical exome of P1 confirmed

the homozygous MFN2 c.1001G>A, p.(Arg334Lys) variant, and also found a novel homozygous

missense variant of unknown significance, c.1454T>A, p.(Ile485Asn), in FOXRED1, a gene

associated with complex I deficiency [4, 20, 22, 31].

Sanger sequencing was used to assess the genetic status of P2. Analysis found

homozygosity for MFN2 Arg334Lys, but only heterozygosity for FOXRED1 Ile485Asn. The family

also had an unaffected sister, for whom no genetic information was obtained.

Based on the genetic work-up from P1, we initially considered both MFN2 R334K and

FOXRED1 I485N variants. Given that the candidate variants in MFN2 and FOXRED1 have not

been described or characterized previously, we examined the conservation of the

corresponding amino acid changes in the protein. We found that the MFN2 R334 residue is

conserved in multiple species, including fruit flies and worms, as well as in the paralogous

protein MFN1, arguing that it plays an important role in protein function (Figure 1a).

Meanwhile, though the FOXRED1 I485 residue is conserved in vertebrates, it is not conserved in

earlier diverging metazoans such as flies or worms (Figure 1b). Upon subsequent sequencing of

P2, who was homozygous for MFN2 R334K, but only heterozygous for and FOXRED1 I485N, it

became evident that MFN2 R334K was most likely the causative variant for the remarkably

consistent phenotype in the two brothers. Topologically, the MFN2 R334K variant is near the

GTPase domain (Figure 1c), which is crucial for mitochondrial fusion [32].

Characterization of patient fibroblasts harboring MFN2 R334K:

As the candidate pathogenic variant in MFN2 is novel and has not been characterized

previously, fibroblasts from a skin biopsy of P1, who harboured homozygous MFN2 R334K and

FOXRED1 I485N variants, were obtained for functional analysis. We examined a variety of

cellular and mitochondrial phenotypes to see which, if any, might be consistent with MFN2

and/or FOXRED1 dysfunction. Unfortunately, fibroblast cells were not available for P2.

Patient fibroblasts show evidence of mitochondrial dysfunction:

Given the integral role of mitochondria in ATP production, we first assessed oxygen

consumption in patient fibroblasts, as this is a key indicator of changes to mitochondrial

function. Compared to control cells, we observed marked decreases in both basal (around half)

and maximal (around two-third) oxygen consumption (Figure 2a), as well as spare respiratory

capacity (Figure 2b). These findings are indicative of severely reduced mitochondrial respiration

in patient fibroblasts, consistent with an underlying mitochondrial dysfunction contributing to

the patient phenotype.

Next, we investigated the canonical function of MFN2 in mitochondrial fusion by

visualizing the mitochondrial network after immunofluorescent labeling for the mitochondrial

marker TOMM20 (Figure 2c). In comparison to the control fibroblasts, which showed elongated

and reticular mitochondrial network morphology, patient fibroblasts qualitatively displayed

more fragmented mitochondrial networks (Figure 2d). Quantitative analysis of the

mitochondrial networks confirmed patient fibroblasts had shorter mitochondria (Figure 2e).

Together, these findings are consistent with impaired mitochondrial fusion leading to more

fragmented mitochondria.

Changes in mitochondrial nucleoids and mtDNA copy number depletion in patient fibroblasts:

To provide further evidence of impaired mitochondrial fusion, we investigated the

distribution and abundance of mtDNA, which can be altered by impairments to mitochondrial

fusion, are linked to loss of MFN2 function, and have been observed for some MFN2 variants

[48, 56, 64]. Immunofluorescence imaging of mtDNA nucleoids (Figure 3a) revealed that the

patient fibroblasts exhibited approximately half as many nucleoids as control fibroblasts (Figure

3b), and that patient mtDNA nucleoids were smaller (Figure 3c). Consistent with the reduced

number of mtDNA nucleoids, we detected a 40% decrease in the mtDNA copy number in the

patient fibroblasts via qPCR (Figure 3d). Finally, we also investigated the presence of mtDNA

deletions, which are sometimes seen with MFN2 loss of function [64]. However, no mtDNA

deletions were detected (Figure 3e).

Altered mito-ER contact sites and lipid droplet accumulation in patient fibroblasts:

We investigated the size and abundance of mito-ER contact sites (MERCs) and lipid

droplets, as these phenotypes can be altered in fibroblasts from patient harboring pathogenic

MFN2 variants [30, 54]. As a proxy for MERCs, we utilized a proximity ligation assay (PLA) that

generates a fluorescent signal when mitochondria and ER are within ~40 nm (Figure 4a-b) [6].

Using confocal microscopy, we observed a decrease in the size and number of MERCs, which

was confirmed by quantitative analyses (Figure 4c-d). We examined lipid droplets using the

neutral lipid droplet dye BODIPY 493/503 (Figure 5a). Compared to control fibroblasts, we

noted a distinct upregulation in the number (Figure 5b) and size (Figure 5c) of lipid droplet

puncta in the R334K patient fibroblasts. These findings of decreased MERCs and increased lipid

droplets are consistent with previously reported alterations in fibroblasts from patients with

CMT2A harbouring MFN2 variants [9, 30].

MFN2 and mitochondrial protein expression:

As our findings were consistent with MFN2 dysfunction, we assessed if expression of

MFN2 and other mitochondrial proteins was impacted. While we did not observe changes in

MFN2 protein levels from total cell lysate (Figure 6a-b), we did observe a significant (~50%)

decrease in expression of the nuclear DNA encoded mitochondrial complex I subunit NDUFB8

(Figure 6a/c). Notably, there was no consistent significant change to the levels of the other

OXPHOS proteins investigated here, including mtDNA-encoded MTCO1. The cause for this

discrepancy in OxPhos protein expression is unknown, but likely does not reflect the mtDNA

depletion, which would be expected to cause a global decrease in OxPhos protein expression as

mtDNA encodes essential proteins for all the electron transport chain complexes except for

complex II.

Complex I activity:

Given the specific decrease in a Complex I protein, which is not typical of MFN2

dysfunction and likely not explained by mtDNA depletion, we wondered if the identified

FOXRED1 missense variant might also have functional consequences that could contribute to

the patient phenotype. As pathogenic defects in FOXRED1 are linked to dysfunction in complex

I assembly and stability, we also examined Complex I activity. Consistent with the reduced

protein expression, and possible complex I instability, we observed an ~50% reduction in

Complex I activity in patient fibroblasts (Figure 6d-e).

***In vitro* re-expression of MFN2 R334K recapitulates Complex-I deficiencies**

To test if the reduced Complex I activity in patient fibroblasts can be explained by the

MFN2 R334K variant alone, we used a knockout re-expression system to test the pathogenicity

of the R334K MFN2 variant in a different genetic background. Using U2OS MFN2 KO cells, we

re-expressed either the WT MFN2 protein or the MFN2 R334K variant by viral transduction,

selecting cells expressing endogenous levels of MFN2 expression (Figure 7c-d). To confirm the

system recapitulates features of patient fibroblasts, we first looked at mitochondrial

morphology. As expected, MFN2 KO cells had severely fragmented mitochondrial networks,

which were rescued by re-expression of the WT protein in KO cells (Figure 7a-b). In line with the

mitochondrial fragmentation observed in patient fibroblasts, we found that MFN2 KO cells re-

expressing MFN2 R334K show partial rescue compared to MFN2 KO cells, but remained more

fragmented than control cells or KO cells re-expressing WT MFN2. Next, we examined the

expression of OxPhos proteins and Complex I function. MFN2 KO cells had severe reductions in

Complexes I, II, III, and IV subunits, which were fully rescued by re-expressing WT MFN2.

However, although Complex II, III and IV protein expression was rescued in MFN2 KO cells re-

expressing the R334K variant, Complex I protein expression was reduced by ~50% compared to

controls (Figure 7c-d). Looking at Complex I activity, MFN2 KO cells showed a marked reduction

that was fully rescued by WT MFN2. Although cells re-expressing MFN2 R334K showed a partial

rescue compared to the KO, there was still a significant 50% decrease compared to controls

(Figure 7e-f). Taken together, these findings confirm previous work showing MFN2 loss of

function can lead to reduced Complex I activity [34, 45], and demonstrate that the MFN2 R334K

variant alone can explain the 50% decrease in Complex I activity observed in patient fibroblasts.

***In vivo* modelling of MFN2 R334K in *Drosophila melanogaster*:**

To model the pathogenicity of the R334K MFN2 variant *in vivo*, we used a knockdown

re-expression paradigm in *Drosophila* (Figure 8a) that has been used to study the function of

other human MFN2 variants [19]. In this approach, depleting the MFN2 orthologue in flies,

marf, can be rescued by re-expressing WT human MFN2 (*hMFN2*). First, we examined the effect

of whole-body knockdown/re-expression using three different driver lines: Actin (*act5c*-Gal4),

Tubulin (*tub*-Gal4) or Daughterless (*da*-Gal4). Whole-body knockdown of *marf* was larval lethal

for all three promoters tested. While *act5c*-Gal4 and *tub*-Gal4 showed no survival, the weaker

da-Gal4 driver had ~10% survival (Figure 8b). Meanwhile, re-expression of WT *hMFN2* rescued

survival to ~60% (Figure 8b), confirming the ability of the WT human MFN2 to function in flies.

In contrast, re-expression of MFN2 R334K was insufficient to rescue the larval lethality (Figure

8b) in any of the whole-body driver lines.

Next, given the larval lethality of the whole-body *marf* knockdown and MFN2 R334K re-

expression, we used a tissue-specific drivers to examine the effects in neurons (*elav*-Gal4) and

cardiomyocytes (*tin*-Gal4), which are relevant to the neuromuscular patient pathology.

Knockdown of *marf* in cardiomyocytes showed no significant lethality (Figure 8c). Next, we

assayed for locomotor function using a negative geotaxis climbing assay. We observed a

marked decrease in climbing ability of flies with knockdown of *marf*, which is nearly completely

rescued by re-expressing WT MFN2, but not by re-expression of MFN2 R334K (Figure 8d). Using

the neuronal driver, we saw 70% survival with *marf* knockdown, which was completely rescued

with WT MFN2, while MFN2 R334K had 95% survival (Figure 8e). In terms of climbing ability

with the neuron driver line *marf* knockdown also led to a significant decrease, which was

completely rescued by WT MFN2 climbing. In contrast, MFN2 R334K provided only a slight

rescue (Figure 8f). Importantly, we confirmed similar levels of WT MFN2 and MFN2 R334K in

our fly lines (Figure 8g). Overall, these data show that the MFN2 R334K variant has reduced

functionality and is unable to rescue *marf* knockdown *in vivo* to the same level as WT MFN2.

Moreover, the deficits seen with neuronal and cardiomyocyte-specific knockdown, reflect the

severe pathology seen in the patient.

Pharmacologic ISR activation rescues MFN2 R334K dysfunction in patient cells

Given our previous work showing ISR activation rescues mitochondrial fragmentation and oxygen consumption in MFN2-deficient cells [5, 8], we speculated that ISR activation would ameliorate dysfunction in MFN2 R334K patient fibroblasts. To this end, a 6-hour treatment with three distinct ISR activators (Halofuginone, 3610, and Parogrelil) completely rescued mitochondrial morphology in R334K patient fibroblasts (Figure 9a-b/Supplemental Figure 1a-d). Furthermore, all three ISR activators also partially rescued OCR deficits (Figure 9c). Importantly, co-treatment with the ISR inhibitor ISRIB prevented the rescue of both morphology and OCR for all three compounds, confirming that this rescue is dependent on ISR activation, rather than any potential off-target effects of the drugs. Overall, these findings show that pharmacological ISR activation is beneficial for MFN2 dysfunction, even for severe perturbations such as those caused by MFN2 R334K.

Discussion:

We report three siblings who presented with severe neonatal encephalopathy, hypotonia, areflexia and arthrogryposis and all three were homozygous for a novel missense variant in MFN2 p.(Arg334Lys). We speculate that the location of the R334K MFN2 variant is crucial for proper protein function, possibly by altering the nearby GTPase domain of the protein. Though CMT2A can be an early-onset disease that can eventually restrict patient movement as the disease progresses, the patients reported here exhibited lack of movement at birth, indicative of a much more severe neonatal onset. Moreover, all three patients succumbed in infancy (<6 weeks) and we would consider this presentation as being neonatal lethal with ventilation. No improvement was observed over their clinical courses. Although areflexia and hypotonia phenotypes are not typical of CMT2A, there are a few previous reports of both phenotypes in patients harbouring MFN2 variants with severe early-onset presentation [35, 43, 48, 51, 57, 65]. However, the patients we report here presented with symptoms immediately upon birth, as opposed to the examples in the previous reports, where symptoms presented from 6-12 months. With respect to the early onset of severe phenotypes linked to MFN2 dysfunction, there is a recent report of a patient with severe CNS complications who

harboured a homozygous 50 amino acid deletion in MFN2 with antenatal presentation that

resulted in pregnancy termination at 31 weeks [13]. In this regard, the fact that loss of MFN2

function leads to embryonic lethality in mice [12] and larval lethality in fruit flies [19], is

consistent with a severe loss of MFN2 function due to the R334K variant.

In support of the notion that the R334K variant impairs MFN2 functions, we observed

changes across all the functions we explored, including mitochondrial network morphology,

oxidative phosphorylation, complex I activity, MERCs, mtDNA copy number and nucleoids, as

well as cellular lipid droplets. These findings suggest that the novel R334K variant causes severe

dysfunction of the MFN2 protein. To our knowledge, there are no previously characterized

MFN2 CMT2a variants with defects across all these functions [64]. However, to some degree

this finding likely reflects the fact that few MFN2 variants have been characterized extensively

for their impact on MFN2 functions, highlighting our limited understanding of how MNF2

variants impact MFN2 functions. In terms of MFN2 variants associated with more severe

cellular phenotypes, it is notable that MFN2 variants that correlate with reduced mtDNA copy

number and impaired oxidative phosphorylation are reported in patients that tend to present

with earlier-onset and severe clinical outcomes [33, 54, 60]. Collectively, this evidence is

consistent with severe MFN2 dysfunction contributing to the very early onset of clinical

symptoms in the patients we report here.

Considering the additional homozygous FOXRED1 variant in P1, it is also worth briefly

discussing the 50% Complex I deficiency in this patient's fibroblasts, which is not typical of

pathogenic MFN2 variants. Notably, complete loss of MFN2 function can lead to a specific

deficit in Complex I expression and function [34], which we also observe in U2OS KO cells.

Moreover, Complex I dysfunction was also reported with the MFN2 variant harbouring a 50

amino acid deletion resulting in pregnancy termination [13]. Thus, MFN2 dysfunction alone is

sufficient to cause Complex I deficiency. Although FOXRED1 is a molecular chaperone important

for the assembly of mitochondrial complex I [22, 42], several lines of evidence argue against a

role for the FOXRED1 I485N the patients' phenotype. First, the patient phenotypes do not

match. Homozygous or compound heterozygous recessive FOXRED1 variants cause

mitochondrial complex I deficiency, nuclear type 19 (MC1DN19), where only a handful of cases

have been described [4, 11, 20, 22, 24, 27, 66]. Clinical phenotypes of MC1DN19 mimic

common mitochondrial disorders such as Leigh syndrome and mitochondrial encephalopathy

[11, 27, 36], including lactic acidosis and growth restrictions. In contrast, there was no evidence

of lactic acidosis in these patients. Meanwhile, though MC1DN19 patients can have hypotonia

[20, 27], and can also be diagnosed with restricted movement accompanying Leigh syndrome

[22], there are no reports of areflexia in FOXRED1 patients, who typically survive well past

infancy [4]. Secondly, the genetics also argue against I485N FOXRED1 variant contributing to

pathology, as FOXRED1 is autosomal recessive, while P2 was heterozygous for the I485N

FOXRED1 variant. Thus, despite the fact that novel I485N FOXRED1 variant reported here is

located at the C-terminus of the protein, similar to other pathogenic FOXRED1 variants

described to date, and the fact that FOXRED1 patient fibroblasts also have reduced Complex I

activity [20] (with patient myoblasts reported with deficiencies in both Complex I and Complex

II [66]), this variant was ruled out as a contributing factor for the phenotype of P1 and P2, who

had identical presentations. Finally, our results in MFN2 KO cells re-expressing the R334K

variant show that this variant alone is sufficient to cause a 50% decrease in Complex I activity,

fully explaining the loss of Complex I activity in patient fibroblasts.

As there is no cure for CMT2A or other MFN2-mediated pathology, it is notable that

pharmacological ISR activation ameliorates the dysfunctions tied to mitochondrial

fragmentation and impaired oxygen consumption in MFN2 R334K patient cells. Notably, one of

the ISR activators we tested, Parogrelil, is an FDA-approved drug that has passed phase I clinical

trials [26, 28]. However, before clinical use for MFN2 pathology, further work is needed to

decipher mechanisms of ISR-dependent rescue, benefits beyond cultured cells, as well as

temporal and dosage effects. Nonetheless, ISR activation is a promising therapeutic

intervention for MFN2-mediated pathology.

Rapid whole exome sequencing (WES) has repeatedly shown that a quicker time to

diagnosis guides goals of clinical care, including less failed treatments, and ultimately lowers

the financial burden on the health care system [14, 23, 37]. While previous reports suggests

that between 30-50% of WES cases are solved or partly solved by a known disease-associated

gene, additional cases may reveal novel genes of uncertain significance (GUS). This study

demonstrates the utility of rapid WES accompanied by functional experiments to assess these

GUS and provide a diagnosis. Functional studies also have the potential to discover new

treatment options for novel genes. However, as this study demonstrates, this is dependent

upon the damaging effects of the variant on the normal function of the gene and/or protein.

Regardless, this study demonstrates the value of collaboration between clinical and research

colleagues.

While we acknowledge the limitations of studying a novel protein variant in a single

family, our functional studies in cells (both in patient fibroblasts and MFN2 KO cells re-

expressing the R334K variant), and in an animal model clearly demonstrate that functional

impairment of the R334K MFN2 variant is sufficient to explain the observed cellular and patient

phenotypes. The fact that that U2OS cells re-expressing the R334K variant recapitulates the key

cellular phenotypes of mitochondrial fragmentation and reduced oxygen consumption show

that this variant, rather than the FOXRED1 variant or some other undetected variant, is

responsible for the observed mitochondrial dysfunction in patient fibroblasts. Meanwhile,

modeling of the R334K variant in *Drosophila* provides *in vivo* evidence that the R334K variant

can explain the severe early onset patient phenotypes. Thus, combined with clear genetic

evidence, this functional work strongly argues for R334K as a novel pathogenic MFN2 variant

causing a severe early onset pathology. This work also highlights the fact that MFN2

dysfunction can cause much more severe pathology than CMT2A typically recognized to be

associated with MFN2 variants.

Acknowledgements

The authors would like to thank the study participants and their family. We would also

like to thank Matthew Lines for his input on the manuscript. We would like to thank Dr. Paul

Marcogliese (University of Manitoba, Canada) for his expertise and technical guidance with the

Drosophila work.

Conflict of Interests

The authors declare that they have no conflict of interest.

Author contributions

Designed and/or performed and analyzed mitochondrial or *Drosophila* experiments, MZ,

CC, SG, RLW and TES; Clinical evaluation of patients and write up, JLM, BM, AMI, FPB; Analyzed

exome data AVP; Drafted the manuscript or figures, MZ, AVP, BM, TES. All authors discussed

the results and commented on the manuscript.

Funding

This work was supported by funds provided by the Canadian Institutes of Health

Research (TES) and the Alberta Children's Hospital Research Institute (Owerko Center) (MZ). MZ

was supported by a Hotchkiss Brain Institute International Recruitment Scholarship. The

funders had no role in study design, data collection and interpretation, or the decision to

submit the work for publication.

Figure Legends:

Figure 1: The MFN2 and FOXRED1 single nucleotide variants are conserved across species. (a) Multiple sequence alignment data shows conservation of MFN2 at Arginine-334 and (b) FOXRED1 conservation of Isoleucine 485. Accession numbers used for comparison are: MFN2: O95140-1; O95140-2; MFN1: Q8IWA4; Mouse MFN2: Q80U63; Fish MFN2: A8WIN6; Fly MFN2: Q7YU24; Worm MFN2: Q23424; FXRD1: Q96CU9; FXRD1 [2]: Q96CU9-2; FXRD1 [3]: Q96CU9-3; Mouse FXRD1: Q3TQB2; Fish FXRD1: A0A0R4IHD6; Fly FXRD1: Q9VJ10; Worm FXRD1: A0A0V1BI76. (c) Topological representation of Mitofusin 2, highlighting the position of MFN2 R334K on the GTPase domain.

Figure 2: MFN2 R334K leads to severe mitochondrial dysfunction: (a) SeaHorse Oxygen Consumption Rate (OCR) indicating control and patient fibroblasts, measured using XF23 extracellular flux analyzer (2 biological replicates with 12 technical replicates). The error bars on the graph indicate the mean OCR +/ SD. (b) Quantification of spare respiratory capacity in control fibroblasts and patient fibroblasts (2 biological replicates with 12 technical replicates); the bars indicate mean +/- SD, statistics are from an unpaired t-test. (c) Representative STED confocal microscopy images showing mitochondrial network morphology in control vs MFN2 R334K patient fibroblasts, stained using anti-TOMM20. (d)Graphical representation of qualitative analysis of mitochondrial branch appearance (fused/intermediate/fragmented), from analysis of 150 images including 3 biological replicates, the bars indicate mean for each category +/ SD, statistics are from an unpaired t-test. (e) Violin plot showing quantitative analyses of mean mitochondrial branch length in control and patient fibroblasts (from 150 cells including 3 biological replicates), with violin plots indicating median and interquartile range (IQR), from an unpaired t-test. Statistical values indicate the following: ns $P > 0.05$, * $P \leq 0.05$, **** $P \leq 0.0001$.

Figure 3: Alterations to mitochondrial DNA in patient fibroblasts. (a) Representative confocal

images showing DAPI (nucleus) and mitochondrial nucleoids (anti-dsDNA) co-localized with the

mitochondrial network (anti-TOMM20) for control (top panels) and patient fibroblasts (bottom

panels). (b) Quantitative analyses of number of mitochondrial nucleoids per cell in control and

patient fibroblasts, the colors indicate biological replicates, the lines indicate mean number of

mito-nucleoids per cell +/ SD, statistics are from an unpaired t-test. (c) Quantitative analyses of

average size(s) of mitochondrial nucleoids in control and patient fibroblasts, the colors indicate

biological replicates, with the lines showing mean +/ SD, statistics are from an unpaired t-test.

(d) Quantitative analysis of mtDNA copy number in control and patient fibroblasts, relative to

18S rDNA, the colors indicate biological replicates, bars indicate mean +/ SD, statistics are from

an unpaired t-test. (e) Representative image of agarose gel to detect mtDNA deletions using

0.6% agarose gel following long-range PCR to target mtDNA amplification and ladder shown on

the left. Statistics shown on the graph represent: ns $P > 0.05$, * $P \leq 0.05$, ** $P \leq 0.01$, **** $P \leq$

0.0001.

Figure 4: Changes to mito-ER contact sites in patient fibroblasts. (a) Top panel shows

representative confocal images of mitochondria (anti-TOMM20) and ER (anti-calnexin) co-

localization, MERCs (PLA probes) and merged images for control fibroblasts. The bottom panel

shows zoomed representation of boxed region. (b) Top panel shows representative confocal

images of mitochondria (anti-TOMM20) and ER (anti-calnexin) co-localization, MERCs (PLA

probes) and merged images for patient fibroblasts. The bottom panel shows zoomed

representation of boxed region. (c) Quantitative analyses of number of PLA signals (MERCs) per

cell in control and patient fibroblasts, colors indicate biological replicates, the violin plots show

distribution of data, while the lines indicate mean +/ SD, statistics are from an unpaired t-test.

(d) Quantitative analyses of average size(s) of PLA puncta (size of MERCs) in control and patient

fibroblasts bars indicate the mean size of PLA puncta +/ SD, statistics are from an unpaired t-

test. Statistics used in the graphs represent the following*** $P \leq 0.001$, **** $P \leq 0.0001$.

Figure 5: Changes to cellular lipid droplet accumulation in control and patient fibroblasts. (a)

Representative confocal images from control (top) and patient (bottom) fibroblasts stained for

lipid droplets using the neutral lipid droplet stain BODIPY™ 493/503. Quantification of average

number (b) and (c) size of lipid droplets per cell in control and patient fibroblasts using

BODIPY™ 493/503. The violin plots indicate median and interquartile ranges, colours indicate

biological replicates and statistics are from an unpaired t-test. The statistics shown are

represented by: **** $P \leq 0.0001$.

Figure 6: MFN2 R334K impedes levels and activity of OXPHOS Complex-I. (a) Representative

Western Blot images from control and MFN2 R334K patient fibroblasts showing protein levels

of MFN2 and the OxPhos complexes, as well as loading control Beta-Actin and mitochondrial

loading control HSP-60. (b) Quantification of MFN2 levels in control fibroblasts and patient

fibroblasts relative to Beta-Actin, colours indicate biological replicates, the bars indicate mean

levels of MFN2 +/ SD, statistics show an unpaired t-test. (c) Quantification of mitochondrial

OxPhos complexes (I-V) levels from Western Blot analyses in control and patient fibroblasts

normalized to cellular beta-actin levels, colours indicate biological replicates, the lines indicate

mean for each category mean +/ SD, statistics are from individual unpaired t-tests versus the

control. (d) Representative images showing dipsticks used to characterize relative complex I

activity in control and patient fibroblasts, using the complex I dipstick assay. (e) Quantification

of relative complex-I activity performed using complex-I dipstick assay in control and patient

fibroblasts, colours indicate biological replicates, while bars indicate mean for each category +/

SD, Statistics shown indicate: ns $P > 0.05$, *** $P \leq 0.001$, **** $P \leq 0.0001$.

Figure 7- *In vitro* modelling of MFN2 R334K shows failure to rescue mitochondrial

fragmentation and complex-I deficiencies. (a) Representative confocal images showing

mitochondrial network morphology, labelled using anti-TOMM20 antibody for WT U2OS, U2OS

MFN2 KO and re-expression of WT MFN2 or MFN2 R334K in KO cells. (b) Quantitative analyses

of mitochondrial network morphology represented by mean mitochondrial branch length,

colours indicate biological replicates, violins plots show the median branch length and inter-

quartile range, statistics were performed using a one-way ANOVA. (c) Representative western

blot images showing re-expression levels of MFN2 (WT/R334K) and corresponding levels of

OXPHOS complex subunits, as well as loading control beta-actin. (d) Quantitative analyses in

WT U2OS/MFN2 KO/WT re-expression/MFN2 R334K re-expression in KO cells showing levels of

proteins (MFN2 re-expression levels and OXPHOS complexes); the colours indicate biological

replicates, bars show the mean protein levels +/- SD, statistics are from an unpaired t-test. (e-f)

Complex-I dysfunction in U2OS MFN2 R334K re-expression cells with (e) representative images

showing complex-I activity dipsticks and (f) Quantitative analyses of complex-I dipstick assay,

the colours indicate biological replicates, the lines show mean complex I activity +/- SD,

statistics are from one-way ANOVA. The statistics represent the following: ns $P > 0.05$, ** $P \leq$

0.01, **** $P \leq 0.0001$.

Figure 8: In vivo analyses of MFN2 R334K using *Drosophila melanogaster* show lethality and

locomotor dysfunctions. (a) Schematic representing Gal4-UAS approach for human disease

modelling in *Drosophila melanogaster*, with Gal4 under the control of whole body/tissue

specific promoters leading to expression of UAS-hMFN2 on chromosome II (phiC31 integrase

approach) and UAS-*marf* RNAi on chromosome III. UAS-*mCherry* RNAi was used as a control for

the Gal4-UAS system. (b) Whole-body survival assay in control, *marf* knockdown and re-

expression of hMFN2 WT and MFN2 R334K fly lines using Actin (*act5c*-Gal4), Tubulin (*tub*-Gal4)

and Daughterless (*da*-Gal4) driver lines. n=80 flies, with four independent replicates. Bars show

mean survivability +/- SD, statistics are from unpaired t-tests. (c) Tissue-specific survival assay

for cardiomyocytes, using control, *marf* knockdown and re-expression of hMFN2 WT and MFN2

R334K fly lines using tinman (*tin*-Gal4) driver line. n=80, with four independent replicates; The

bars on the graph show mean survival +/- SD, statistics are from unpaired t-tests. (d) Negative

geotaxis assay to look for climbing ability of flies with changes to cardiomyocytes *(tin)*

knockdown and re-expression of human MFN2, lines show mean +/- SD, statistics are from

unpaired t-tests at each time point for WT-re=expression vs R334K re-expression. (e) Tissue-

specific survival assay for neurons, using control, *marf* knockdown and re-expression of hMFN2

702 WT and MFN2 R334K fly lines using elav (*elav*-Gal4) driver line. n=80, with four independent

703 replicates; The bars on the graph show mean survival +/- SD, statistics are from unpaired t-

704 tests. (f) Negative geotaxis assay to look for climbing ability of flies with changes to neurons

705 *(elav)* knockdown and re-expression of human MFN2, lines show mean +/- SD, statistics are

706 from unpaired t-tests at each time point for WT-re-expression vs R334K re-expression.

707 (f)Representative Western Blot images showing expression of human MFN2 protein expression

708 in in control, *marf* knockdown and re-expression of hMFN2 WT and MFN2 R334K fly lines under

709 the control of *elav*-Gal4. (b) Statistics represent the followingns P > 0.05, * P≤ 0.05, ** P ≤ 0.01,

710 **** P ≤ 0.0001.

712 Figure 9: ISR activation rescues mitochondrial fragmentation and boosts cellular oxygen

713 consumption in MFN2 R334K patient cells. (a) Representative confocal images showing

714 mitochondrial network morphology using MitoTracker green for control fibroblasts vs MFN2

715 R334K patient fibroblasts treated with ISR activators/inhibitors for 6 hours with vehicle, #3610

716 (10uM), Parogrelil (10uM) and Halofuginone (100nM), along with ISRIB (200nM). (b)

717 Quantitative analyses of mitochondrial network morphology for control/patient fibroblasts

718 treated with ISR activators, points on the graph indicate biological replicates, lines show mean

719 mitochondrial branch length +/- SD, statistics come from one-way ANOVA. (c) Quantitative

720 analyses of cellular oxygen consumption rate measured using Resipher OCR, for control

721 fibroblasts and patient fibroblasts treated for 6 hours with vehicle, #3610 (10uM), Parogrelil

722 (10uM) and Halofuginone (100nM), along with ISRIB (200nM). Colours indicate biological

723 replicates, violin plots show the median OCR and IQR, one-way ANOVA. Statistics on the graphs

724 represent the following: ns P > 0.05, * P≤ 0.05, **** P ≤ 0.0001.

726 Supplemental Figure S1: ISR activation rescues mitochondrial fragmentation and boosts cellular

727 oxygen consumption. (A) Representative confocal images showing mitochondrial network

728 morphology using MitoTracker green for control fibroblasts treated with the following ISR

729 activators/inhibitors for 6 hours with vehicle, #3610 (10uM), Parogrelil (10uM) and

Halofuginone (100nM), along with ISRIB (200nM). (b) Quantitative analyses of mitochondrial

network morphology for control fibroblasts treated with ISR activators, points indicate

biological replicates, bars show mean +/- SD, statistics represent a one-way ANOVA. (c)

Representative confocal images showing mitochondrial network morphology using MitoTracker

green for MFN2 R334K patient fibroblasts treated with ISR activators/inhibitors for 6 hours with

vehicle, #3610 (10uM), Parogrelil (10uM) and Halofuginone (100nM), along with ISRIB (200nM).

(d) Quantitative analyses of mitochondrial network morphology for patient fibroblasts, colours

indicate biological replicates, symbols indicate means of biological replicates, lines show mean

+/- SD, one-way ANOVA. (e) Quantitative analyses of cellular oxygen consumption rate

measured using Resipher OCR, for control fibroblasts and patient fibroblasts treated for 6 hours

with vehicle, #3610 (10uM), Parogrelil (10uM) and Halofuginone (100nM), along with ISRIB

(200nM). Colours indicate biological replicates, violin plots show median and IQR, statistics

represent a one-way ANOVA. Statistical symbols represent ns $P > 0.05$, * $P \leq 0.05$, **** $P \leq$

0.0001.

References:

1. Ainbinder A, Boncompagni S, Protasi F, Dirksen RT (2015) Role of Mitofusin-2 in mitochondrial localization and calcium uptake in skeletal muscle. Cell Calcium 57:14–24. doi: 10.1016/j.ceca.2014.11.002

2. Amiott EA, Lott P, Soto J, Kang PB, McCaffery JM, DiMauro S, Abel ED, Flanigan KM, Lawson VH, Shaw JM (2008) Mitochondrial fusion and function in Charcot-Marie-Tooth type 2A patient fibroblasts with mitofusin 2 mutations. Exp Neurol 211:115–127. doi: 10.1016/j.expneurol.2008.01.010

3. Anderson NS, Haynes CM (2020) Folding the Mitochondrial UPR into the Integrated Stress Response. Trends Cell Biol 30:428–439. doi: 10.1016/j.tcb.2020.03.001

4. Apatean D, Rakic B, Brunel-Guitton C, Hendson G, Bai R, Sargent MA, Lavoie PM, Patel M, Stockler-Ipsiroglu S (2019) Congenital lactic acidosis, cerebral cysts and pulmonary hypertension in an infant with FOXRED1 related complex I deficiency. Mol Genet Metab Rep 18:32–38. doi: 10.1016/j.ymgmr.2018.12.006

5. Baron KR, Oviedo S, Krasny S, Zaman M, Aldakhlallah R, Mathur P, Pfeffer G, Bollong MJ, Shutt T, Grotjahn DA, Wiseman RL (2024) Pharmacologic Activation of Integrated Stress Response Kinases Inhibits Pathologic Mitochondrial Fragmentation. eLife 13. doi: 10.7554/eLife.100541.1

6. Benhammouda S, Vishwakarma A, Gatti P, Germain M (2021) Mitochondria Endoplasmic Reticulum Contact Sites (MERCs): Proximity Ligation Assay as a Tool to Study Organelle Interaction. Front Cell Dev Biol 9:789959. doi: 10.3389/fcell.2021.789959

7. Bombelli F, Stojkovic T, Dubourg O, Echaniz-Laguna A, Tardieu S, Larcher K, Amati-Bonneau P, Latour P, Vignal O, Cazeneuve C, Brice A, Leguern E (2014) Charcot-Marie-Tooth Disease Type 2A: From Typical to Rare Phenotypic and Genotypic Features. JAMA Neurology 71:1036–1042. doi: 10.1001/jamaneurol.2014.629

8. Bora P, Zaman M, Oviedo S, Kutseikin S, Madrazo N, Mathur P, Pannikkat M, Krasny S, Chu A, Johnson KA, Grotjahn DA, Shutt TE, Wiseman RL (2025) Drug Repurposing Screen Identifies an HRI Activating Compound that Promotes Adaptive Mitochondrial Remodeling in MFN2-deficient Cells. 2025.06.23.660251

9. Boutant M, Kulkarni SS, Joffraud M, Ratajczak J, Valera-Alberni M, Combe R, Zorzano A, Cantó C (2017) Mfn2 is critical for brown adipose tissue thermogenic function. EMBO J 36:1543–1558. doi: 10.15252/embj.201694914

10. de Brito OM, Scorrano L (2008) Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 456:605–610. doi: 10.1038/nature07534

11. Calvo SE, Tucker EJ, Compton AG, Kirby DM, Crawford G, Burtt NP, Rivas M, Guiducci C, Bruno DL, Goldberger OA, Redman MC, Wiltshire E, Wilson CJ, Altshuler D, Gabriel SB, Daly MJ, Thorburn DR, Mootha VK (2010) High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency. Nat Genet 42:851–858. doi: 10.1038/ng.659

12. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC (2003) Mitofusins Mfn1 and Mfn2
coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell
Biol 160:189–200. doi: 10.1083/jcb.200211046

13. Chevrollier A, Bonnard AA, Ruaud L, Gueguen N, Perrin L, Desquiret-Dumas V, Guimiot F, Becker P-
H, Levy J, Reynier P, Gaignard P (2024) Homozygous MFN2 variants causing severe antenatal
encephalopathy with clumped mitochondria. Brain 147:91–99. doi: 10.1093/brain/awad347

14. Chung CCY, Leung GKC, Mak CCY, Fung JLF, Lee M, Pei SLC, Yu MHC, Hui VCC, Chan JCK, Chau JFT,
Chan MCY, Tsang MHY, Wong WHS, Tung JYL, Lun KS, Ng YK, Fung CW, Wong MSC, Wong RMS, Lau
YL, Chan GCF, Lee SL, Yeung KS, Chung BHY (2020) Rapid whole-exome sequencing facilitates
precision medicine in paediatric rare disease patients and reduces healthcare costs. Lancet Reg
Health West Pac 1:100001. doi: 10.1016/j.lanwpc.2020.100001

15. Chung KW (2006) Early onset severe and late-onset mild Charcot-Marie-Tooth disease with
mitofusin 2 (MFN2) mutations. Brain 129:2103–2118. doi: 10.1093/brain/awl174

16. Detmer SA, Chan DC (2007) Complementation between mouse Mfn1 and Mfn2 protects
mitochondrial fusion defects caused by CMT2A disease mutations. J Cell Biol 176:405–414. doi:
10.1083/jcb.200611080

17. Di Tommaso P, Moretti S, Xenarios I, Orobitg M, Montanyola A, Chang J-M, Taly J-F, Notredame C
(2011) T-Coffee: a web server for the multiple sequence alignment of protein and RNA sequences
using structural information and homology extension. Nucleic Acids Res 39:W13-17. doi:
10.1093/nar/gkr245

18. Eaton JS, Lin ZP, Sartorelli AC, Bonawitz ND, Shadel GS (2007) Ataxia-telangiectasia mutated kinase
regulates ribonucleotide reductase and mitochondrial homeostasis. J Clin Invest 117:2723–2734.
doi: 10.1172/JCI31604

19. Eschenbacher WH, Song M, Chen Y, Bhandari P, Zhao P, Jowdy CC, Engelhard JT, Dorn GW (2012)
Two rare human mitofusin 2 mutations alter mitochondrial dynamics and induce retinal and
cardiac pathology in Drosophila. PLoS One 7:e44296. doi: 10.1371/journal.pone.0044296

20. Fassone E, Duncan AJ, Taanman J-W, Pagnamenta AT, Sadowski MI, Holand T, Qasim W, Rutland P,
Calvo SE, Mootha VK, Bitner-Glindzicz M, Rahman S (2010) FOXRED1, encoding an FAD-dependent
oxidoreductase complex-I-specific molecular chaperone, is mutated in infantile-onset
mitochondrial encephalopathy. Hum Mol Genet 19:4837–4847. doi: 10.1093/hmg/ddq414

21. Feely SME, Laura M, Siskind CE, Sottile S, Davis M, Gibbons VS, Reilly MM, Shy ME (2011) MFN2
mutations cause severe phenotypes in most patients with CMT2A. Neurology 76:1690–1696. doi:
10.1212/WNL.0b013e31821a441e

22. Formosa LE, Mimaki M, Frazier AE, McKenzie M, Stait TL, Thorburn DR, Stroud DA, Ryan MT (2015)
Characterization of mitochondrial FOXRED1 in the assembly of respiratory chain complex I. Hum
Mol Genet 24:2952–2965. doi: 10.1093/hmg/ddv058

23. Freed AS, Clowes Candadai SV, Sikes MC, Thies J, Byers HM, Dines JN, Ndugga-Kabuye MK, Smith
MB, Fogus K, Mefford HC, Lam C, Adam MP, Sun A, McGuire JK, DiGeronimo R, Dipple KM, Deutsch

820 GH, Billimoria ZC, Bennett JT (2020) The Impact of Rapid Exome Sequencing on Medical
821 Management of Critically Ill Children. J Pediatr 226:202-212.e1. doi: 10.1016/j.jpeds.2020.06.020

822 24. Haack TB, Madignier F, Herzer M, Lamantea E, Danhauser K, Invernizzi F, Koch J, Freitag M, Drost R,
823 Hillier I, Haberberger B, Mayr JA, Ahting U, Tiranti V, Rötig A, Iuso A, Horvath R, Tesarova M, Baric
824 I, Uziel G, Rolinski B, Sperl W, Meitinger T, Zeviani M, Freisinger P, Prokisch H (2012) Mutation
825 screening of 75 candidate genes in 152 complex I deficiency cases identifies pathogenic variants in
826 16 genes including NDUFB9. J Med Genet 49:83–89. doi: 10.1136/jmedgenet-2011-100577

827 25. Hikiami R, Yamashita H, Koita N, Jingami N, Sawamoto N, Furukawa K, Kawai H, Terashima T, Oka
828 N, Hashiguchi A, Takashima H, Urushitani M, Takahashi R (2018) Charcot-Marie-Tooth disease type
829 2A with an autosomal-recessive inheritance: the first report of an adult-onset disease. J Hum
830 Genet 63:89–92. doi: 10.1038/s10038-017-0353-3

831 26. Hori M, Iwama T, Asakura Y, Kawanishi M, Kamon J, Hoshino A, Takahashi S, Takahashi K, Nakaike
832 S, Tsuruzoe N (2009) NT-702 (parogrelil hydrochloride, NM-702), a novel and potent
833 phosphodiesterase 3 inhibitor, suppress the asthmatic response in guinea pigs, with both
834 bronchodilating and anti-inflammatory effects. Eur J Pharmacol 618:63–69. doi:
835 10.1016/j.ejphar.2009.07.005

836 27. Hu C, Xu Q, Shen J, Wang Y (2021) Clinical and Genetic Characteristics of Mitochondrial
837 Encephalopathy Due to FOXRED1 Mutations: Two Chinese Case Reports and a Review of the
838 Literature. Front Neurol 12:633397. doi: 10.3389/fneur.2021.633397

839 28. Ishiwata N, Noguchi K, Kawanishi M, Asakura Y, Hori M, Mitani A, Ito Y, Takahashi K, Nishiyama H,
840 Shudo N, Takahashi S, Takahashi K, Tsuruzoe N, Nakaike S (2007) NT-702 (parogrelil hydrochloride,
841 NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and
842 lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication
843 model. Life Sci 81:970–978. doi: 10.1016/j.lfs.2007.07.025

844 29. Kimura Y, Nishikawa A, Hashiguchi A, Etoh M, Yoshimura A, Asai K, Miyashita N, Takashima H, Sumi
845 H, Naka T (2022) An MFN2-related Charcot-Marie-Tooth Disease Patient with Optic Nerve Atrophy,
846 Neurogenic Bladder Dysfunction, and Diaphragmatic Weakness. Intern Med 61:1743–1747. doi:
847 10.2169/internalmedicine.6487-20

848 30. Larrea D, Pera M, Gonnelli A, Quintana-Cabrera R, Akman HO, Guardia-Laguarta C, Velasco KR,
849 Area-Gomez E, Dal Bello F, De Stefani D, Horvath R, Shy ME, Schon EA, Giacomello M (2019) MFN2
850 mutations in Charcot-Marie-Tooth disease alter mitochondria-associated ER membrane function
851 but do not impair bioenergetics. Hum Mol Genet 28:1782–1800. doi: 10.1093/hmg/ddz008

852 31. Lemire BD (2015) Evolution of FOXRED1, an FAD-dependent oxidoreductase necessary for
853 NADH:ubiquinone oxidoreductase (Complex I) assembly. Biochim Biophys Acta 1847:451–457. doi:
854 10.1016/j.bbabio.2015.01.014

855 32. Li Y-J, Cao Y-L, Feng J-X, Qi Y, Meng S, Yang J-F, Zhong Y-T, Kang S, Chen X, Lan L, Luo L, Yu B, Chen
856 S, Chan DC, Hu J, Gao S (2019) Structural insights of human mitofusin-2 into mitochondrial fusion
857 and CMT2A onset. Nat Commun 10:4914. doi: 10.1038/s41467-019-12912-0

33.   Loiseau D, Chevrollier A, Verny C, Guillet V, Gueguen N, Pou de Crescenzo M-A, Ferré M, Malinge
M-C, Guichet A, Nicolas G, Amati-Bonneau P, Malthièry Y, Bonneau D, Reynier P (2007)
Mitochondrial coupling defect in Charcot-Marie-Tooth type 2A disease. Ann Neurol 61:315–323.
doi: 10.1002/ana.21086

34.   Luo N, Yue F, Jia Z, Chen J, Deng Q, Zhao Y, Kuang S (2021) Reduced electron transport chain
complex I protein abundance and function in Mfn2-deficient myogenic progenitors lead to
oxidative stress and mitochondria swelling. FASEB J 35:e21426. doi: 10.1096/fj.202002464R

35.   Madrid R, Guariglia SR, Haworth A, Korosh W, Gavin M, Lyon GJ (2020) Early-onset cerebellar
ataxia in a patient with CMT2A2. Cold Spring Harb Mol Case Stud 6:a005108. doi:
10.1101/mcs.a005108

36.   Marra F, Lunetti P, Curcio R, Lasorsa FM, Capobianco L, Porcelli V, Dolce V, Fiermonte G, Scarcia P
(2021) An Overview of Mitochondrial Protein Defects in Neuromuscular Diseases. Biomolecules
11:1633. doi: 10.3390/biom11111633

37.   McDermott H, Sherlaw-Sturrock C, Baptista J, Hartles-Spencer L, Naik S (2022) Rapid exome
sequencing in critically ill children impacts acute and long-term management of patients and their
families: A retrospective regional evaluation. Eur J Med Genet 65:104571. doi:
10.1016/j.ejmg.2022.104571

38.   McLelland G-L, Goiran T, Yi W, Dorval G, Chen CX, Lauinger ND, Krahn AI, Valimehr S, Rakovic A,
Rouiller I, Durcan TM, Trempe J-F, Fon EA (2018) Mfn2 ubiquitination by PINK1/parkin gates the
p97-dependent release of ER from mitochondria to drive mitophagy. eLife 7:e32866. doi:
10.7554/eLife.32866

39.   Mick E, Titov DV, Skinner OS, Sharma R, Jourdain AA, Mootha VK Distinct mitochondrial defects
trigger the integrated stress response depending on the metabolic state of the cell. eLife 9:e49178.
doi: 10.7554/eLife.49178

40.   Misko A, Jiang S, Wegorzewska I, Milbrandt J, Baloh RH (2010) Mitofusin 2 is necessary for
transport of axonal mitochondria and interacts with the Miro/Milton complex. J Neurosci 30:4232–
4240. doi: 10.1523/JNEUROSCI.6248-09.2010

41.   Nicholson GA, Magdelaine C, Zhu D, Grew S, Ryan MM, Sturtz F, Vallat J-M, Ouvrier RA (2008)
Severe early-onset axonal neuropathy with homozygous and compound heterozygous MFN2
mutations. Neurology 70:1678–1681. doi: 10.1212/01.wnl.0000311275.89032.22

42.   Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong S-E, Walford GA, Sugiana C, Boneh A, Chen
WK, Hill DE, Vidal M, Evans JG, Thorburn DR, Carr SA, Mootha VK (2008) A mitochondrial protein
compendium elucidates complex I disease biology. Cell 134:112–123. doi:
10.1016/j.cell.2008.06.016

43.   Pellino G, Faggioli R, Galuppi A, Leon A, Fusco C, Tugnoli V, Suppiej A (2021) Mitofusin 2: The
missing link between mtDNA maintenance defects and neurotransmitter disorders. Mitochondrion
61:159–164. doi: 10.1016/j.mito.2021.09.011

44.   Perkins LA, Holderbaum L, Tao R, Hu Y, Sopko R, McCall K, Yang-Zhou D, Flockhart I, Binari R, Shim
896   H-S, Miller A, Housden A, Foos M, Randkelv S, Kelley C, Namgyal P, Villalta C, Liu L-P, Jiang X, Huan-
897   Huan Q, Wang X, Fujiyama A, Toyoda A, Ayers K, Blum A, Czech B, Neumuller R, Yan D, Cavallaro A,
898   Hibbard K, Hall D, Cooley L, Hannon GJ, Lehmann R, Parks A, Mohr SE, Ueda R, Kondo S, Ni J-Q,
899   Perrimon N (2015) The Transgenic RNAi Project at Harvard Medical School: Resources and
900   Validation. Genetics 201:843–852. doi: 10.1534/genetics.115.180208

901   45.   Pich S, Bach D, Briones P, Liesa M, Camps M, Testar X, Palacín M, Zorzano A (2005) The Charcot–
902   Marie–Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of
903   OXPHOS system. Human Molecular Genetics 14:1405–1415. doi: 10.1093/hmg/ddi149

904   46.   Polke JM, Laurá M, Pareyson D, Taroni F, Milani M, Bergamin G, Gibbons VS, Houlden H, Chamley
905   SC, Blake J, Devile C, Sandford R, Sweeney MG, Davis MB, Reilly MM (2011) Recessive axonal
906   Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations. Neurology
907   77:168–173. doi: 10.1212/WNL.0b013e3182242d4d

908   47.   Quirós PM, Mottis A, Auwerx J (2016) Mitonuclear communication in homeostasis and stress. Nat
909   Rev Mol Cell Biol 17:213–226. doi: 10.1038/nrm.2016.23

910   48.   Renaldo F, Amati-Bonneau P, Slama A, Romana C, Forin V, Doummar D, Barnerias C, Bursztyn J,
911   Mayer M, Khouri N, Billette de Villemeur T, Burglen L, Reynier P, Bernabe Gelot A, Rodriguez D
912   (2012) MFN2, a new gene responsible for mitochondrial DNA depletion. Brain 135:e223, 1–4;
913   author reply e224, 1–3. doi: 10.1093/brain/aws111

914   49.   Rizzo F, Bono S, Ruepp MD, Salani S, Ottoboni L, Abati E, Melzi V, Cordiglieri C, Pagliarani S, De
915   Gioia R, Anastasia A, Taiana M, Garbellini M, Lodato S, Kunderfranco P, Cazzato D, Cartelli D, Lonati
916   C, Bresolin N, Comi G, Nizzardo M, Corti S (2023) Combined RNA interference and gene
917   replacement therapy targeting MFN2 as proof of principle for the treatment of Charcot-Marie-
918   Tooth type 2A. Cell Mol Life Sci 80:373. doi: 10.1007/s00018-023-05018-w

919   50.   Rocha AG, Franco A, Krezel AM, Rumsey JM, Alberti JM, Knight WC, Biris N, Zacharioudakis E,
920   Janetka JW, Baloh RH, Kitsis RN, Mochly-Rosen D, Townsend RR, Gavathiotis E, Dorn GW (2018)
921   MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease
922   type 2A. Science 360:336–341. doi: 10.1126/science.aao1785

923   51.   Rouzier C, Bannwarth S, Chaussenot A, Chevrollier A, Verschueren A, Bonello-Palot N, Fragaki K,
924   Cano A, Pouget J, Pellissier J-F, Procaccio V, Chabrol B, Paquis-Flucklinger V (2012) The MFN2 gene
925   is responsible for mitochondrial DNA instability and optic atrophy "plus" phenotype. Brain 135:23–
926   34. doi: 10.1093/brain/awr323

927   52.   Sabouny R, Wong R, Lee-Glover L, Greenway SC, Sinasac DS, Care4Rare Canada, Khan A, Shutt TE
928   (2019) Characterization of the C584R variant in the mtDNA depletion syndrome gene FBXL4,
929   reveals a novel role for FBXL4 as a regulator of mitochondrial fusion. Biochim Biophys Acta Mol
930   Basis Dis 1865:165536. doi: 10.1016/j.bbadis.2019.165536

931   53.   Sawyer SL, Cheuk-Him Ng A, Innes AM, Wagner JD, Dyment DA, Tetreault M, Care4Rare Canada
932   Consortium, Majewski J, Boycott KM, Screaton RA, Nicholson G (2015) Homozygous mutations in
933   MFN2 cause multiple symmetric lipomatosis associated with neuropathy. Hum Mol Genet
934   24:5109–5114. doi: 10.1093/hmg/ddv229

54. Sharma G, Zaman M, Sabouny R, Joel M, Martens K, Martino D, De Koning APJ, Pfeffer G, Shutt TE
(2022) Characterization of a novel variant in the HR1 domain of MFN2 in a patient with ataxia,
optic atrophy and sensorineural hearing loss. F1000Res 10:606. doi:
10.12688/f1000research.53230.2

55. Sidarala V, Zhu J, Levi-D'Ancona E, Pearson GL, Reck EC, Walker EM, Kaufman BA, Soleimanpour SA
(2022) Mitofusin 1 and 2 regulation of mitochondrial DNA content is a critical determinant of
glucose homeostasis. Nat Commun 13:2340. doi: 10.1038/s41467-022-29945-7

56. Silva Ramos E, Motori E, Brüser C, Kühl I, Yeroslaviz A, Ruzzenente B, Kauppila JHK, Busch JD,
Hultenby K, Habermann BH, Jakobs S, Larsson N-G, Mourier A (2019) Mitochondrial fusion is
required for regulation of mitochondrial DNA replication. PLoS Genet 15:e1008085. doi:
10.1371/journal.pgen.1008085

57. Tan CA, Rabideau M, Blevins A, Westbrook MJ, Ekstein T, Nykamp K, Deucher A, Harper A, Demmer
L (2016) Autosomal recessive MFN2-related Charcot-Marie-Tooth disease with diaphragmatic
weakness: Case report and literature review. Am J Med Genet A 170:1580–1584. doi:
10.1002/ajmg.a.37611

58. UniProt Consortium (2023) UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids
Res 51:D523–D531. doi: 10.1093/nar/gkac1052

59. Valente AJ, Maddalena LA, Robb EL, Moradi F, Stuart JA (2017) A simple ImageJ macro tool for
analyzing mitochondrial network morphology in mammalian cell culture. Acta Histochem 119:315–
326. doi: 10.1016/j.acthis.2017.03.001

60. Vielhaber S, Debska-Vielhaber G, Peeva V, Schoeler S, Kudin AP, Minin I, Schreiber S, Dengler R,
Kollewe K, Zuschratter W, Kornblum C, Zsurka G, Kunz WS (2013) Mitofusin 2 mutations affect
mitochondrial function by mitochondrial DNA depletion. Acta Neuropathol 125:245–256. doi:
10.1007/s00401-012-1036-y

61. Winter JM, Yadav T, Rutter J (2022) Stressed to death: Mitochondrial stress responses connect
respiration and apoptosis in cancer. Mol Cell 82:3321–3332. doi: 10.1016/j.molcel.2022.07.012

62. Zacharioudakis E, Agianian B, Kumar MV V, Biris N, Garner TP, Rabinovich-Nikitin I, Ouchida AT,
Margulets V, Nordstrøm LU, Riley JS, Dolgalev I, Chen Y, Wittig AJH, Pekson R, Mathew C, Wei P,
Tsirigos A, Tait SWG, Kirshenbaum LA, Kitsis RN, Gavathiotis E (2022) Modulating mitofusins to
control mitochondrial function and signaling. Nat Commun 13:3775. doi: 10.1038/s41467-022-
31324-1

63. Zaman M, Sharma G, Almutawa W, Soule TG, Sabouny R, Joel M, Mohan A, Chute C, Joseph JT,
Pfeffer G, Shutt TE (2025) The MFN2 Q367H variant reveals a novel pathomechanism connected to
mtDNA-mediated inflammation. Life Sci Alliance 8:e202402921. doi: 10.26508/lsa.202402921

64. Zaman M, Shutt TE (2022) The Role of Impaired Mitochondrial Dynamics in MFN2-Mediated
Pathology. Front Cell Dev Biol 10:858286. doi: 10.3389/fcell.2022.858286

65. Züchner S, De Jonghe P, Jordanova A, Claeys KG, Guergueltcheva V, Cherninkova S, Hamilton SR,
Van Stavern G, Krajewski KM, Stajich J, Tournev I, Verhoeven K, Langerhorst CT, de Visser M, Baas

F, Bird T, Timmerman V, Shy M, Vance JM (2006) Axonal neuropathy with optic atrophy is caused
by mutations in mitofusin 2. Ann Neurol 59:276–281. doi: 10.1002/ana.20797

66. Zurita Rendón O, Antonicka H, Horvath R, Shoubridge EA (2016) A Mutation in the Flavin Adenine
Dinucleotide-Dependent Oxidoreductase FOXRED1 Results in Cell-Type-Specific Assembly Defects
in Oxidative Phosphorylation Complexes I and II. Mol Cell Biol 36:2132–2140. doi:
10.1128/MCB.00066-16

(a)

Arginine 334

317   355

MFN2_HUMAN	AQGMPEGGGALAEGFQVRMFEFQNFERRFEECISQSAVK
MFN1_HUMAN	AQGMPESGVALAEGFHARLQEFQNFEQIFEECISQSAVK
MFN2_MOUSE	AQGMPEGGGALAEGFQVRMFEFQNFERQFEECISQSAVK
MFN2_FISH	AQGMPEAGGALAEGFQARMFEFQNFERRFEECISQSAVK
MFN_FRUITFLY_Tr	AKGNPPHMGAIAEGFQIRYFEFQDFERKFEECISQSAVK
MFN_WORM_Transm	ARGLVQK-AYQAEGHGTRALEFQNFERHFEHCISRSAIH

cons   :   ***.   *   ***:**: ** .***:**::

(b)

Isoleucine 485

475   486

FXRD1_HUMAN	YLGEKIQENNI-I
FXRD1_MOUSE	YLGEKLQEYNI-L
FXRD1_FISH	IKKKPILERNI-V
FXRD1_FRUITFLY	IVDQPMFELNNVLS
FXRD1_WORM	LRGKTVKPECF--

cons   : :

(c)

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Figure 9